Zoetis’ premium animal-health franchise is wounded by competitive and safety headwinds, but the valuation now prices in far more permanent damage than the long-term moat may justify.
Overview
Zoetis is the global leader in animal health, operating across more than 100 countries with a diversified portfolio of medicines, vaccines, diagnostics, genetic tests, and biologics. Companion animals drive 70% of revenue, supported by durable pet humanization trends, while livestock provides resilient exposure to global protein demand. The company’s integrated diagnostics, therapeutics, and digital platforms create strong customer retention. Despite near-term pressure in U.S. companion animal products, Zoetis remains a high-margin, globally scaled franchise with meaningful long-term secular support.